News

The Phase I study is a randomized, double-blind and placebo-controlled single ascending dose study to evaluate the safety and tolerability as well as the pharmacokinetic profile of ACR343

The results show that patients receiving 150mg of PRX-03140 orally once daily as monotherapy achieved a mean 5.7 point improvement on the Alzheimer’s Disease Assessment Scale cognitive subscale

The payment is the second of two triggered by the December 2006 FDA approval of Elestrin, a treatment for reducing hot flashes associated with menopause, and brings the

Under the new agreement, Confirma will offer program consultation, experienced applications training, customizable educational courses, and marketing and reimbursement consultation to GE Healthcare customers with CADstream, the standard

Under the terms of the agreement, Affymetrix will pay approximately $75 million in cash to acquire USB. The transaction is expected to close in the first quarter of

Preclinical results demonstrated that COTI-2 inhibited Akt/PKB phosphorylation in cancer cells resulting in apoptosis or programmed cell death and has shown excellent in vitro activity in several human

In this study of patients suffering from post-herpetic neuralgia, Eladur showed improved pain control versus placebo during the three-day continuous treatment period. In addition, Eladur appeared well tolerated

The POET-II (Essential Tremor II) program is a two-part registration program that will begin with a clinical study in subjects in up to 15 centers to acquire a

Published data on ranolazine’s mechanism suggests that during ischemic episodes excess sodium can flow into cardiac cells through sodium channels. This excess sodium can trigger a subsequent overload